Navigation Links
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
Date:8/7/2009

pany's products to market, including loss of market share as a result of the suspension of shipments, and related costs; (26) sale or licensing of certain assets; (27) the ability to monetize the auction rate securities (ARS) currently held by the Company, the amount of proceeds to be received from such monetization and the timing of receipt of proceeds by the Company; (28) the timing and ability to realize and receive expected tax refunds, the actual refund amount to be received by the Company subject to any challenges or otherwise and the timing of receipt of the refund by the Company; (29) the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, other indebtedness of the Company; and (30) the risks detailed from time-to-time in the Company's filings with the SEC.

This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements. The Company is under no obligation to update any of the forward-looking statements after the date of this press release. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-looking Statements" and the risk factors that are included under the heading "Item 1A--Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2008, as supplemented by the Company's subsequent SEC filings.


'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
2. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
5. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. ADVENTRX Pharmaceuticals Announces Financing
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 "In America," the ... the United States that is hosted by legendary film actor ... topic of botany in an upcoming segment. , Botany ... in reality it is actually quite a bit more complicated ... of different types of living organisms, from the smallest bacteria ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalystâ„¢ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... YORK , March 25, 2015  S&P ... commenced Factual Stock Report coverage on Abattis ... (OTCQX: ATTBF; CSE: ATT): is a specialty biotechnology ... of cultivating, licensing and marketing proprietary ingredients, bio-similar ... markets in North America . ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... the cleanest, greenest and far and away most abundant ... woefully under-utilized. High costs have been a major deterrant ... - densely packed nanoscale arrays of optically active semiconductors ... of relatively cheap and scalable solar cells, but have ...
... 17, 2010 Nanotrope, Inc. announced today that it ... ground-breaking diagnostic test for influenza and other viral infections. ... an artificial "cell" engineered with specific membrane compositions and ... mimic as it would a normal host cell.  Once ...
... American Heart Association Late Breaker Session ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A new twist for nanopillar light collectors 2A new twist for nanopillar light collectors 3Nanotrope, Inc. Receives Patent on New Diagnostic Test for Influenza and Other Viral Infections 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2
... Putnam Valley, NY. (Dec. 18, 2013) ... therapy for acute liver failure, either for liver ... However, maintaining the viability and functional aspects of ... freezing (cryopreservation). In an effort to improve both ...
... Institute of Science and Technology (UNIST) announced a method ... which led to the fabrication of a graphene-based field ... opportunities for practical use in electronic devices. ... research team led by Prof. Jong-Beom Baek have discovered ...
... Cell biologists at the Ruhr-Universitt Bochum (RUB) have launched ... enzyme Parkin in promoting neuronal survival. The team of ... Physiological Chemistry, Department of Molecular Cell Biology, is looking ... Michael J. Fox Foundation finances this research project with ...
Cached Biology News:Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation 2UNIST research team opens graphene band-gap 2
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
... LabChip 3000 drug discovery system miniaturizes, ... assays. Using LabChip technology, the ... a serial, continuous flow fashion. LabChip ... of results exceeds what is achievable ...
... fast and reliable automation for today's ... development laboratories. Staccato Mini-Workstations offer the ... basic liquid handling and material management ... either Caliper's time proven CLARA™ assay ...
Biology Products: